Re: New Trust Intelligence article on Omidria's ability to reduce opiate use
Alan,
I read the 2015 J Cataract paper - thanks for the link in your online report. Just a few things to point out for those interested in this thread:
1. One author is an employee of Omeros with an equity interest. The other authors are all OMER consultants
2. The authors don't actually count the number of opioid prescriptions written on the day of surgery for the placebo group, and then written for the Tx group, day of surgery. There is just a throw-away footnote that "most commonly administered analgesics included paracetamol and fentanyl". It could be that prescriptions for paracetamol were reduced in the tx group and fentanyl were about the same for each group - there are no confidence intervals provided
3. The only time OMER mentions opioid reduction in their May 22 corporate presentation is on Slide 11 in small font. But what they are doing is citing a footnote from one of their own employees. Citing one of your own employees as the source for opioid reduction is not the strongest move I've ever seen - esp when that employee doesn't seem to have counted opioid prescriptions issued in his study
4. The magnitude of post-operative pain reduction is solid; and the authors make a good case that 27% of those patients are likely to be in the moderate to severe category (based on a lit review - it was lower in their study); but no one actually counted an opioid use drop on a per mg basis, or prescriptions written basis.
5. I think this paper is a good start, but OMER can do better - and I really hope they will do better as a long. When I look at corporate presentations by PCRX they are screaming opioid reduction at the top of their lungs - they don't want anyone to miss the point. I can't say this is the case with OMER looking at the May22 corporate presentation.